BerGenBio: Promising Data Highlighting Selective AXL Inhibitor Bemcentinib's Potential to Improve Efficacy of Checkpoint Inhibitors Presented at AACR

BERGEN, Norway, April 18, 2018 /PRNewswire/ -- BerGenBio ASA (BGBIO.OL), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that promising preclinical data with its lead ...

Combination of Checkpoint Inhibitors and Intezyne's Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy

TAMPA, Fla., April 10, 2018 /PRNewswire/ -- Intezyne, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced exciting results from their ongoing preclinical studies of novel cancer resistance pathway inhibitor IT-139 ...

Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting

James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “These data demonstrate CK-103’s potential to be a novel BET inhibitor that potently inhibits MYC expression. Elevated levels of MYC proteins are found in 60-70% of all ...